Cancer Guidelines Database

Access quality cancer guidelines from a single Canadian source

We've listed guidelines under your selection of "Type of cancer". The most recent guidelines are first.

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016

Year: 2017
AGREE II score: Unavailable
Developer organization: Mayo Clinic
This is a clinical practice guideline for patients with Waldenström macroglobulinemia (WM). The guideline discusses a risk-adapted approach to the management of WM, using a grading system. Topics of interest include diagnosis, risk stratification and response assessment, initial therapy, as well as subsequent therapy.

The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Hematologic Malignancies: Multiple Myeloma, Lymphoma, and Acute Leukemia

Year: 2016
AGREE II score: Available
Developer organization: Society for Immunotherapy of Cancer
This is a clinical practice guideline for patients with hematologic malignancies. The guideline specifically examines immunotherapy for the treatment of multiple myeloma, lymphoma, and acute leukemia. Topics of interest include patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies.

Allogeneic Hematopoietic Stem Cell Transplantation for MDS and CMML: Recommendations from an International Expert Panel

Year: 2017
AGREE II score: Unavailable
Developer organization: European Blood and Marrow Transplant Society
This is a clinical practice guideline for patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The guideline examines the use of allogeneic hematopoietic stem cell transplantation (HSCT) as a curative treatment option. Topics of interest include factors of relevance for selection of the source of hematopoietic cells, timing of transplantation, factors relevant for selecting the intensity of preparatory regimens, and post-transplantation strategies.

ECIL-6 Guidelines for the Treatment of Invasive Candidiasis, Aspergillosis and Mucormycosis in Leukemia and Hematopoietic Stem Cell Transplant Patients

Year: 2017
AGREE II score: Unavailable
Developer organization: European Conference on Infections in Leukemia (ECIL)
This is a clinical practice guideline for patients with hematologic malignancies or recipients of hematopoietic stem cell transplantation. The guideline examines diagnostic strategies as well as prophylactic, pre-emptive or targeted therapy for various types of infections in these patients. Invasive candidiasis or aspergillosis infections, and mucormycosis are discussed. Both first-line treatment and salvage and maintenance therapy are addressed.

Guidelines for Diagnosis, Prevention and Management of Central Nervous System Involvement in Diffuse Large B-cell Lymphoma Patients by the Spanish Lymphoma Group (GELTAMO)

Year: 2017
AGREE II score: Unavailable
Developer organization: Spanish Lymphoma Group
This is a clinical practice guideline for patients with central nervous system (CNS) diffuse large B-cell lymphoma who have or at risk of developing leptomeningeal and/or brain parenchyma lymphoma relapse. The guideline examines the treatment of central nervous system involvement of lymphoma using whole-brain radiotherapy, systemic chemotherapy, intensification chemotherapy and autologous hematopoietic stem cell transplantation, and intrathecal therapy. Risk factors, diagnostic screening, and CNS prophylaxis are also discussed.

Treatment of Patients With Waldenström Macroglobulinaemia: Clinical Practice Guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Year: 2017
AGREE II score: Unavailable
Developer organization: Myeloma Australia
This is a clinical practice guideline for patients with Waldenström macroglobulinemia (WM). The guideline examines the diagnosis and treatment of these patients. Common presentations, diagnostic criteria, prognostic markers, as well as diagnostic workup using protein studies and bone marrow biopsy are considered. Therapeutic regiments are discussed for front-line therapy of WM and treatment of relapsed WM, as well as important management aspects unique to WM.

ECIL Guidelines for Treatment of Pneumocystis Jirovecii Pneumonia in Non-HIV-Infected Haematology Patients

Year: 2016
AGREE II score: Unavailable
Developer organization: European Conference on Infections in Leukemia (ECIL)
This is a clinical practice guideline for non-HIV-infected hematology patients. The guideline examines the treatment of Pneumocystis jirovecii pneumonia (PCP) in these patients. First-line treatment including selection of drugs and route of administration is discussed, as well as assessment of treatment response, second-line treatment, drug-related side-effects and drug-drug interactions, treatment duration, intensive care, glucocorticosteroids as adjuvant therapy, and secondary anti-PCP prophylaxis. The symptoms of PCP in hematology patients, criteria for initiation of PCP treatment, and grading of PCP severity and prognostic factors are also addressed.

ECIL Guidelines for Preventing Pneumocystis Jirovecii Pneumonia in Patients With Haematological Malignancies and Stem Cell Transplant Recipients

Year: 2016
AGREE II score: Unavailable
Developer organization: European Conference on Infections in Leukemia (ECIL)
This is a clinical practice guideline for patients with hematological disorders who are at risk for Pneumocystis jirovecii pneumonia (PCP). The guideline focuses on the prevention of PCP, and specifically examines PCP diagnosis, prophylaxis and treatment. Differences in clinical presentations between hematology patients and other immunocompromised populations, especially HIV-infected patients, are discussed.

ECIL Guidelines for the Diagnosis of Pneumocystis Jirovecii Pneumonia in Patients With Haematological Malignancies and Stem Cell Transplant Recipients

Year: 2016
AGREE II score: Unavailable
Developer organization: European Conference on Infections in Leukemia (ECIL)
This is a clinical practice guideline for the diagnosis of Pneumocystis jirovecii pneumonia (PCP) in patients following treatment for hematological malignancies or after hematopoietic stem cell transplantation (HSCT). This guideline highlights the main differences in clinical presentation of PCP between hematology patients and other immunocompromised populations, especially HIV-infected patients, and the main risks factors including pre-existing respiratory disease, and genetic predisposition. The risk factors associated with specific therapies, such as corticosteroids, chemotherapeutic agents, and monoclonal antibodies are also addressed.

Management of Viral Hepatitis in Patients With Haematological Malignancy and in Patients Undergoing Haemopoietic Stem Cell Transplantation: Recommendations of the 5th European Conference on Infections In Leukaemia (ECIL-5)

Year: 2016
AGREE II score: Unavailable
Developer organization: European Conference on Infections in Leukemia (ECIL)
This is a clinical practice guideline for the management of viral hepatitis in patients with hematological malignancy and in patients undergoing haemopoietic stem cell transplantation. The guideline examines the screening, vaccination, and treatment options for these conditions. Primary outcomes of interest include the prevention of viral reactivation, and increasing overall survival.